SOUTHWESTERN VERMONT MEDICAL CENTER
1. Target Overview & Investment Thesis
SOUTHWESTERN VERMONT MEDICAL CENTER is a 57-bed under-performing / distressed in BENNINGTON, VT with $154.6M in net patient revenue and a -26.6% operating margin. The hospital serves a payer mix of 41.7% Medicare, 12.6% Medicaid, and 45.7% commercial.
Thesis: Turnaround. Our ML models identify $11.4M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -26.6% to -19.2% (+736bps).
| Net Revenue HCRIS | $154.6M |
| Current EBITDA COMPUTED | $-41.1M |
| Operating Margin COMPUTED | -26.6% |
| Occupancy HCRIS | 66.1% |
| Revenue / Bed COMPUTED | $2.7M |
| Net-to-Gross HCRIS | 35.7% |
| Distress Probability ML | 45.4% |
2. Market Context & Competitive Position
VT has 16 Medicare-certified hospitals with a median operating margin of -26.6%. The target's margin of -26.6% places it below the state median. Among 2074 size-comparable peers (28-114 beds), the median margin is -3.1%. The target's below-peer margin suggests operational improvement opportunity.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (28-114), prioritizing same-state peers. 2074 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| SOUTHWESTERN VERMONT MEDICAL C (Target) | VT | 57 | $154.6M | -26.6% |
| DANA-FARBER CANCER INSTITUTE | MA | 30 | $1.88B | -35.1% |
| MIDWESTERN REGIONAL MEDICAL CE | IL | 73 | $1.38B | 80.5% |
| RANCHO LOS AMIGOS NATL.REHAB.C | CA | 83 | $512.6M | 41.9% |
| USC NORRIS CANCER HOSPITAL | CA | 60 | $468.7M | 19.1% |
| THE HEART HOSPITAL BAYLOR PLAN | TX | 109 | $464.6M | 25.7% |
| SARAH BUSH LINCOLN HEALTH CENT | IL | 100 | $448.6M | -18.1% |
| ST. JOSEPHS COMM. HOSPT. | WI | 70 | $436.8M | 66.1% |
| MCHS FRANCISCAN HEALTHCARE IN | WI | 103 | $413.8M | -7.2% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $11.4M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $3.2M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $3.1M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $3.1M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $1.9M | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $99K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $-41.1M |
| + RCM Uplift | +$11.4M |
| Pro Forma EBITDA | $-29.7M |
| Current Margin | -26.6% |
| Pro Forma Margin | -19.2% |
| WC Released (1x) | $5.9M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $-63.3M | $-157.5M | 0.00x | -100.0% |
| Base (11x exit) | 10.0x | 11.0x | $-63.3M | $-193.8M | 0.00x | -100.0% |
| Bull Case | 9.0x | 11.0x | $-56.9M | $-176.8M | 0.00x | -100.0% |
| Bull (12x exit) | 9.0x | 12.0x | $-56.9M | $-209.7M | 0.00x | -100.0% |
| Bear Case | 11.0x | 10.0x | $-69.6M | $-193.8M | 0.00x | -100.0% |
| Bear (11x exit) | 11.0x | 11.0x | $-69.6M | $-235.8M | 0.00x | -100.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Negative operating margin | RCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 2074 hospitals with 28-114 beds
- Same-state prioritization (n=5)
- Comp margins: P25=-16.4% / P50=-3.1% / P75=8.9%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.